CLAIMS

1. A method for treating pathological conditions caused by reduced production of erythropoietin, comprising administering a cyclic amine compound represented by the following formula (1):

$$R^{2} = \begin{vmatrix} R^{1} & & & \\ - & & & \\ R^{3} & & & \\ & & & \\ R^{3} & & & \\ & & &$$

wherein,

R¹, R² and R³ each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W¹ and W² each independently represent N or CH;

X represents O, NR⁴, CONR⁴ or NR⁴CO;

R⁴ each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof in an effective amount to a need thereof.

- 2. The method according to claim 1, wherein R^1 , R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1 - C_8 -alkyl group, a halogen-substituted C_1 - C_8 -alkyl, an alkoxy group having a C_1 - C_8 -alkyl group, an alkylthio group having a C_1 - C_8 -alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1 - C_6 -alkyl group, or an alkanoyl group having a C_1 - C_6 -alkyl group.
- 3. The method to claim 1, wherein R⁴ each represents a hydrogen atom, a C₁-C₈-alkyl

group, C₃-C₈-alkenyl group, C₃-C₈-alkynyl group, substituted or unsubstituted C₆-C₁₄-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C₆-C₁₄-aryl-C₁-C₆-alkyl group, or C₁-C₆-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

- 4. The method according to claim 3, wherein in R⁴, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.
- 5. The method according to claim 1, wherein the active ingredient is 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine or a salt thereof.
- 6. A method for treating anemia, comprising administering a cyclic amine compound represented by the following formula (1):

$$R^{2} = \begin{vmatrix} R^{1} & & & \\ - & & \\ R^{3} & & & \\ & & & \\ R^{3} & & & \\$$

wherein,

R¹, R² and R³ each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W¹ and W² each independently represent N or CH;

X represents O, NR⁴, CONR⁴ or NR⁴CO;

R⁴ each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof in an effective thereof to a need thereof.

- 7. The method according to claim 6, wherein R^1 , R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1 - C_8 -alkyl group, a halogen-substituted C_1 - C_8 -alkyl, an alkoxy group having a C_1 - C_8 -alkyl group, an alkylthio group having a C_1 - C_8 -alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1 - C_6 -alkyl group, or an alkanoyl group having a C_1 - C_6 -alkyl group.
- 8. The method according to claim 6, wherein R^4 each represents a hydrogen atom, a C_1 - C_8 -alkyl group, C_3 - C_8 -alkenyl group, C_3 - C_8 -alkynyl group, substituted or unsubstituted C_6 - C_{14} -aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C_6 - C_{14} -aryl- C_1 - C_6 -alkyl group, or C_1 - C_6 -alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.
- 9. The method according to claim 8, wherein in R⁴, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.
- 10. The method according to claim 6, wherein the active ingredient is 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-

1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine or a salt thereof.

11. A method for treating chronic anemia, renal anemia, anaplastic anemia or pure red cell aplasia, comprising administering a cyclic amine compound represented by the following formula (1):

$$R^{2} = \begin{vmatrix} R^{1} & & & \\ - & & \\ R^{3} & & \\ & & \\ R^{3} & & \\ &$$

wherein,

R¹, R² and R³ each independently represent a hydrogen atom, a halogen atom, or hydroxy, alkyl, halogen-substituted alkyl, alkoxy, alkylthio, carboxyl, alkoxycarbonyl or alkanoyl group;

W¹ and W² each independently represent N or CH;

X represents O, NR⁴, CONR⁴ or NR⁴CO;

R⁴ each represents a hydrogen atom, or an alkyl, alkenyl, alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaralkyl group; and

l, m and n each represents a number of 0 or 1, or a salt thereof or a solvate thereof in an effective amount to a need thereof.

- 12. The method according to claim 11, wherein R^1 , R^2 and R^3 are each a hydrogen atom, a halogen atom, a hydroxy group, a C_1 - C_8 -alkyl group, a halogen-substituted C_1 - C_8 -alkyl, an alkoxy group having a C_1 - C_8 -alkyl group, an alkylthio group having a C_1 - C_8 -alkyl group, a carboxyl group, an alkoxycarbonyl group having a C_1 - C_6 -alkyl group, or an alkanoyl group having a C_1 - C_6 -alkyl group.
- 13. The method according to claim 11, wherein R⁴ each represents a hydrogen atom, a

C₁-C₈-alkyl group, C₃-C₈-alkenyl group, C₃-C₈-alkynyl group, substituted or unsubstituted C₆-C₁₄-aryl group, substituted or unsubstituted heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms, substituted or unsubstituted C₆-C₁₄-aryl-C₁-C₆-alkyl group, or C₁-C₆-alkyl group having heteroaryl group having 5- or 6-membered ring containing 1-4 nitrogen atoms.

14. The method according to claim 13, wherein in R⁴, the substituent of an aryl group, an aryl group of aralkyl group, heteroaryl group, or heteroaryl group of heteroaralkyl group is 1-3 groups selected from the group consisting of alkyl group, alkoxy group, alkylthio group, a halogen atom, a nitro group, an amino group, an acetylamino group, trifluoromethyl group and alkylenedioxy group.

15. The preventive or therapeutic agent according to claim 11, wherein the active ingredient is

4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridine-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridine-4-yl]methyl]piperidine or a salt thereof.